HomeCompareHBANN vs ABBV

HBANN vs ABBV: Dividend Comparison 2026

HBANN yields 30.41% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 HBANN wins by $34.4K in total portfolio value
10 years
HBANN
HBANN
● Live price
30.41%
Share price
$25.09
Annual div
$7.63
5Y div CAGR
0.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$136.8K
Annual income
$18,472.25
Full HBANN calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — HBANN vs ABBV

📍 HBANN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHBANNABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HBANN + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HBANN pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HBANN
Annual income on $10K today (after 15% tax)
$2,585.15/yr
After 10yr DRIP, annual income (after tax)
$15,701.41/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $5,354.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HBANN + ABBV for your $10,000?

HBANN: 50%ABBV: 50%
100% ABBV50/50100% HBANN
Portfolio after 10yr
$119.5K
Annual income
$21,622.00/yr
Blended yield
18.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

HBANN
Analyst Ratings
1
Buy
2
Hold
Consensus: Hold
Price Target
$16.20
-35.4% upside vs current
Range: $14.50 — $18.00
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HBANN buys
0
ABBV buys
0
No recent congressional trades found for HBANN or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHBANNABBV
Forward yield30.41%3.06%
Annual dividend / share$7.63$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0.1%40.6%
Portfolio after 10y$136.8K$102.3K
Annual income after 10y$18,472.25$24,771.77
Total dividends collected$94.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$16.20$256.15

Year-by-year: HBANN vs ABBV ($10,000, DRIP)

YearHBANN PortfolioHBANN Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$13,744$3,044.39$11,550$430.00+$2.2KHBANN
2$18,621$3,914.50$13,472$627.96+$5.1KHBANN
3$24,886$4,961.40$15,906$926.08+$9.0KHBANN
4$32,831$6,203.04$19,071$1,382.55+$13.8KHBANN
5$42,785$7,655.70$23,302$2,095.81+$19.5KHBANN
6$55,113$9,333.43$29,150$3,237.93+$26.0KHBANN
7$70,219$11,247.54$37,536$5,121.41+$32.7KHBANN
8$88,540$13,406.18$50,079$8,338.38+$38.5KHBANN
9$110,552$15,814.05$69,753$14,065.80+$40.8KHBANN
10$136,763$18,472.25$102,337$24,771.77+$34.4KHBANN

HBANN vs ABBV: Complete Analysis 2026

HBANNStock

Huntington Bancshares Incorporated operates as a holding company for The Huntington National Bank that provides commercial, small business, consumer, and mortgage banking services. The company operates through four business segments: Consumer and Business Banking, Commercial Banking, Vehicle Finance, and Regional Banking and The Huntington Private Client Group (RBHPCG). The Consumer and Business Banking segment offers financial products and services, such as checking accounts, savings accounts, money market accounts, certificates of deposit, consumer loans, mortgage loans, credit cards, and small business loans, as well as investment products. It also provides insurance, interest rate risk protection, foreign exchange, and treasury management services, as well as online, mobile, and telephone banking services. The Commercial Banking segment offers banking solutions and asset finance services; corporate risk management services; institutional sales, trading, and underwriting services; institutional corporate banking services; treasury management services; and other financing solutions, as well as lends real estate developers, REITs, and other customers. The Vehicle Finance segment provides financing to consumers for the purchase of automobiles, light-duty trucks, recreational vehicles, and marine craft at franchised and other select dealerships, as well as to franchised dealerships for the acquisition of new and used inventory. The RBHPCG segment provides deposits, lending, banking, wealth management, investment and portfolio management, fiduciary administration, trust, retirement plan, and institutional and mutual fund custody services. As of January 23, 2020, the company operated through 868 full-service branches, including 12 private client group offices, and 1,448 automated teller machines located in 7 Midwestern states. Huntington Bancshares Incorporated was founded in 1866 and is headquartered in Columbus, Ohio.

Full HBANN Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this HBANN vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HBANN vs SCHDHBANN vs JEPIHBANN vs OHBANN vs KOHBANN vs MAINHBANN vs JNJHBANN vs MRKHBANN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.